Early cirrhosis often causes no obvious pain: fatigue, sleep changes, bruising, itch, and a falling platelet count may arrive before jaundice. The useful clue is usually a pattern across liver tests, blood count, and fibrosis scores—not one abnormal enzyme.
- Silent scarring can occur with normal ALT and AST, particularly in metabolic fatty liver disease and alcohol-related liver disease.
- Plàtaidean fo 150 × 10⁹/L can be an early portal-hypertension clue when they fall gradually alongside liver risk factors.
- FIB-4 fo 1.3 usually indicates low risk of advanced fibrosis in adults under 65; 2.67 or higher warrants prompt specialist assessment.
- Albumin fo 35 g/L or a rising INR can indicate reduced liver synthetic function, even if aminotransferases are modest.
- AST:ALT above 1 is not diagnostic of cirrhosis, but it raises concern when paired with thrombocytopenia, elevated GGT, or imaging changes.
- Bilirubin above 34 µmol/L with jaundice, dark urine, fever, confusion, or abdominal swelling needs urgent clinical assessment.
- Normal enzymes mean no active enzyme leak at that moment; they do not prove that liver architecture is normal.
- Alcohol cessation, metabolic risk treatment, viral hepatitis care, and medication review can slow or sometimes partially reverse earlier-stage fibrosis.
Subtle early cirrhosis symptoms that deserve a liver check
Early cirrhosis symptoms are often vague and intermittent, with fatigue, reduced appetite, disturbed sleep, itch, easy bruising, or reduced exercise tolerance occurring long before yellow skin or fluid retention. In my clinical experience, the concerning feature is not one tired afternoon; it is a quiet cluster that persists for 6 to 12 weeks in someone with diabetes, obesity, regular alcohol exposure, hepatitis risk, or a family history of liver disease.
A person may still work, train, and look entirely well while fibrosis advances. I have seen a 48-year-old office worker whose only change was waking at 3 a.m. with itching and fatigue; his ALT was 31 IU/L, but platelets had drifted from 214 to 136 × 10⁹/L over four years. That trend prompted elastography and identified advanced fibrosis.
Cirrhosis does not usually cause sharp liver pain. The liver capsule can stretch late in the process, but early scarring is biologically quiet because fibrosis develops between microscopic vascular channels. A new sense of abdominal fullness, early satiety, or ankle swelling is more concerning than a vague right-sided ache, especially when weight increases by more than 2 kg in a week.
Dr. Thomas Klein advises bringing prior results, not merely the newest panel, to a liver review. A deuchainn fala bunaiteach becomes far more useful when it can be compared with results from 12, 24, and 48 months earlier.
Symptoms that should not wait for a routine appointment
Confusion, new daytime sleepiness, vomiting blood, black stool, fever with abdominal swelling, or rapidly increasing jaundice require same-day emergency assessment. These can reflect decompensated cirrhosis, gastrointestinal bleeding, infection, or acute liver injury rather than a harmless fluctuation.
Why normal ALT and AST do not rule out cirrhosis
Normal ALT and AST do not exclude significant fibrosis or cirrhosis. ALT and AST reflect current cellular enzyme leakage, whereas fibrosis reflects accumulated architectural scarring that may produce little ongoing leakage once liver cell mass and inflammation decline.
Many laboratories use ALT upper limits around 35 to 45 IU/L for men and 25 to 35 IU/L for women, although reference intervals vary by assay and country. A result of 28 IU/L can be normal on paper while still being less reassuring in a person with obesity, type 2 diabetes, a platelet count of 128 × 10⁹/L, and a high FIB-4 score.
The 2023 AASLD guidance states that aminotransferases may be normal in patients with advanced non-alcoholic fatty liver disease; risk stratification should therefore include non-invasive fibrosis testing rather than enzymes alone (Rinella et al., 2023). This is one of those areas where the pattern matters more than the flag beside a single value.
Hard training, muscle injury, and some medicines can raise AST without liver scarring. A 52-year-old marathon runner with AST 89 IU/L after a race may have a muscle source, particularly if creatine kinase is high and bilirubin, platelets, INR, and GGT are normal; our high AST guide a’ mìneachadh an eadar-dhealachaidh sin.
Cirrhosis blood tests: the pattern clinicians actually worry about
The most concerning cirrhosis blood-test pattern combines falling platelets, AST exceeding ALT, elevated bilirubin or GGT, and impaired albumin or INR rather than an isolated enzyme rise. Each test captures a different aspect of liver biology: injury, bile flow, portal pressure, or protein production.
Plàtaidean fo 150 × 10⁹/L are common in advanced fibrosis because portal hypertension enlarges the spleen and increases platelet pooling. A count of 142 × 10⁹/L is not proof of cirrhosis, yet a downward trajectory from 240 to 142 is clinically more meaningful than one isolated result.
An AST:ALT ratio above 1.0 can occur as fibrosis advances, while ratios above 2.0 are classically associated with alcohol-related hepatitis but are neither sensitive nor specific. GGT often rises with alcohol, metabolic fatty liver, cholestasis, and medication effects; read more about what GGT means before assuming alcohol is the cause.
Kantesti AI interprets liver panels by weighing these linked results against age, sex, reported conditions, and prior values rather than assigning a diagnosis from one flag. Kantesti ’s e anailisiche deuchainn fala AI a th’ ann designed to identify follow-up patterns such as low platelets plus rising AST:ALT ratio, which deserve clinician review.
The common false reassurance trap
A normal bilirubin and normal albumin can coexist with compensated cirrhosis. Those markers often deteriorate later, after the liver has lost more functional reserve, so they are poor stand-alone screening tests for early scarring.
FIB-4 and non-invasive clues to clinically significant scarring
FIB-4 is a validated first-line fibrosis score using age, AST, ALT, and platelet count. In adults younger than 65, a FIB-4 below 1.3 generally indicates low risk of advanced fibrosis, while a result of 2.67 or higher should trigger specialist assessment or elastography.
The formula is age × AST divided by platelets × the square root of ALT, with AST and ALT in IU/L and platelets in × 10⁹/L. Age changes the score substantially: EASL recommends a higher low-risk threshold of 2.0 for people older than 65 because ordinary age-related scoring can otherwise produce false positives (European Association for the Study of the Liver, 2021).
A FIB-4 score is a triage tool, not a diagnosis. Acute hepatitis, a recent heavy alcohol episode, chemotherapy, or a transient platelet fall can inflate it, so I usually repeat unstable tests in 4 to 12 weeks before interpreting a borderline result unless the person has jaundice or other red flags.
Tha Kantesti na seirbheis eadar-mhìneachaidh deuchainn-lann AI that can calculate and contextualize FIB-4 when the necessary results are present, but a high score needs medical confirmation with transient elastography, specialist assessment, or occasionally tissue examination. Our liver-panel overview shows which tests are commonly available.
Low platelets: an early portal-hypertension clue, not a verdict
A persistent platelet count below 150 × 10⁹/L can be one of the earliest routine blood-test clues to portal hypertension, but it has many non-liver causes. The liver link becomes stronger when counts decline gradually and occur with splenic enlargement, high FIB-4, or abnormal liver imaging.
Portal hypertension changes the circulation through the liver and spleen. The spleen may retain more platelets, so a count of 110 to 140 × 10⁹/L can precede ascites or varices by years in compensated disease. That is why platelet trend is included in FIB-4 rather than treated as a generic CBC footnote.
Not every low result reflects a true fall. EDTA-related platelet clumping can falsely lower a count, and the laboratory can confirm this with a blood-film review or a citrate sample; see our explanation of cruinneachadh pleitean EDTA. Viral illness, immune thrombocytopenia, folate deficiency, and marrow conditions also remain possible.
Dr. Thomas Klein has found that a count falling by 20% across two years is often more useful than asking whether it has crossed a laboratory lower limit. Pair it with the complete blood count components and prior ultrasound reports before drawing conclusions.
Albumin and INR: blood tests that measure liver reserve
Low albumin and a prolonged INR can signal reduced liver synthetic function, especially when they develop together. Albumin below 35 g/L or an INR above 1.3 without anticoagulant treatment warrants timely clinical review, although neither result is specific to cirrhosis.
Albumin has a half-life of roughly 20 days, so it changes slowly and often remains normal in compensated cirrhosis. Malnutrition, kidney protein loss, severe systemic illness, pregnancy, and fluid overload can also lower albumin; the stiùireadh albumin agus globulin helps separate these possibilities.
INR reflects vitamin K-dependent clotting factor activity, much of which is produced by the liver. An INR of 1.5 in a person not taking warfarin is more concerning than a mildly raised ALT, but vitamin K deficiency from malabsorption, antibiotics, or cholestasis can also prolong it and may be reversible.
Kantesti AI ’s e Inneal mion-sgrùdaidh deuchainn fala le cumhachd AI that highlights albumin, bilirubin, INR, and platelet patterns together because synthetic function is not captured by ALT alone. For technical context on clotting assays, review our stiùireadh deuchainn clotadh againn.
Jaundice, itch, dark urine, and pale stool: what they may mean
Jaundice, dark tea-coloured urine, pale stool, and generalised itch can indicate impaired bile flow or impaired bilirubin processing and should be assessed promptly. A total bilirubin above 34 µmol/L, about 2 mg/dL, often becomes visible as yellowing in daylight, though skin tone and lighting affect detection.
Dark urine is usually caused by conjugated bilirubin, not by bilirubin that is unconjugated. A urine dipstick positive for bilirubin therefore points clinicians toward hepatobiliary disease or obstruction rather than simple red-cell breakdown; our stiùireadh bilirubin ann am fual explains the next checks.
Pale or clay-coloured stool means less pigment is reaching the bowel. It may occur with a gallstone, medication-related cholestasis, pancreatic or bile-duct disease, or advanced liver dysfunction, so it is not safe to label it a detox reaction; see adhbharan stòl bàn.
Itch from cholestasis can be severe before bilirubin becomes strikingly high. It commonly affects palms and soles and worsens at night; clinicians usually check ALP, GGT, bilirubin fractions, medication exposure, pregnancy status where relevant, and ultrasound access to the bile ducts.
ALP, GGT, and bilirubin: recognising a cholestatic pattern
A cholestatic liver-test pattern means alkaline phosphatase and GGT rise more than ALT and AST, often with direct bilirubin elevation. This pattern should prompt a search for bile-duct obstruction, medication injury, autoimmune cholestatic disease, or infiltrative liver conditions rather than an automatic assumption of cirrhosis.
ALP is produced by bile-duct tissue but also by bone, placenta, and intestine. An elevated ALP with a normal GGT may be bone-derived, particularly after a fracture, during growth, or with vitamin D deficiency, whereas high ALP plus high GGT supports a hepatobiliary source; our ALP and GGT explanation a’ toirt eisimpleirean practaigeach.
The R ratio helps classify acute enzyme patterns: ALT divided by its upper limit of normal, then divided by ALP divided by its upper limit. An R ratio above 5 suggests hepatocellular injury, below 2 suggests cholestasis, and 2 to 5 is mixed—useful for medication assessment but not a stand-alone diagnosis.
Kantesti AI uses laboratory reference limits from the uploaded report rather than imposing a universal ALP cutoff, because ranges differ. The cholestasis blood-test guide is useful preparation for a clinician discussion.
Finding the cause matters as much as finding the scar
Cirrhosis is an endpoint, not a single disease: alcohol, metabolic fatty liver disease, hepatitis B or C, autoimmune disease, iron overload, and some medications can all cause it. Identifying the cause changes treatment, family screening, cancer surveillance, and the chance of slowing further fibrosis.
Metabolic risk deserves a direct conversation. Central weight gain, triglycerides above 1.7 mmol/L or 150 mg/dL, hypertension, and type 2 diabetes increase the likelihood of steatotic liver disease, even when alcohol intake is low. A metabolic syndrome checklist can clarify the associated risks.
Ferritin above 300 ng/mL in men or postmenopausal women is not enough to diagnose iron overload. Transferrin saturation persistently above 45% is more specific for hereditary haemochromatosis and usually prompts HFE genetic testing in an appropriate clinical setting; see our haemochromatosis symptoms guide.
Medication and supplement histories are routinely underestimated. High-dose green tea extract, anabolic agents, multi-ingredient weight-loss products, amiodarone, methotrexate, and some antibiotics can alter liver tests, while a supposed liver cleanse may delay proper evaluation; our supplement safety review is deliberately cautious about this.
Viral hepatitis should be tested, not guessed from symptoms
Chronic hepatitis C can remain asymptomatic for decades while fibrosis progresses. Antibody testing identifies exposure, while an HCV RNA test confirms active infection; our stiùireadh deuchainn hepatitis C explains why both tests matter.
What happens after an abnormal cirrhosis blood-test pattern
An abnormal fibrosis pattern usually leads to repeat blood tests, an ultrasound, and elastography rather than an immediate diagnosis of cirrhosis. Elastography estimates liver stiffness in kilopascals and is most reliable when acute inflammation, congestion, and recent heavy alcohol exposure are considered.
A clinician commonly repeats AST, ALT, ALP, GGT, bilirubin, albumin, INR, and full blood count within weeks if results are unexpected. They may add hepatitis B and C tests, ferritin with transferrin saturation, immunoglobulins, autoantibodies, coeliac testing, and ceruloplasmin in younger adults—although the exact list follows age and risk history.
EASL's 2021 non-invasive-test guideline supports a two-step approach: first FIB-4, then transient elastography or a second serum test for people above the low-risk threshold (European Association for the Study of the Liver, 2021). Liver stiffness is not identical to fibrosis; heart failure congestion, cholestasis, and acute hepatitis can temporarily raise it.
Tha Kantesti na àrd-ùrlar mìneachaidh biomarcadairean AI that can organise an uploaded panel into questions for the next appointment, including which values changed and what potential causes need exclusion. Our clinical methodology is described in the geàrr-shealladh dearbhaidh meidigeach, but it does not replace an examination or imaging order.
Alcohol, metabolic risk, and when to repeat liver tests
Alcohol reduction and metabolic risk treatment can improve liver enzymes within weeks, but fibrosis risk should not be judged from one improved ALT result. GGT often declines over 2 to 6 weeks after alcohol cessation, while platelet and fibrosis-score changes may take longer and depend on the underlying disease stage.
There is no universally safe alcohol threshold for a person with established cirrhosis; abstinence is the standard recommendation because even small amounts may worsen portal hypertension or interfere with recovery. For people without cirrhosis, reported intake still needs context: binge patterns, body weight, diabetes, and medication use modify risk considerably.
In metabolic liver disease, a sustained 7% to 10% body-weight reduction is associated with improvement in steatohepatitis and can improve fibrosis in some patients, although individual results vary. Crash dieting can transiently raise ALT, so interpret a panel alongside recent weight change; our article on enzymes grùthan às deidh call cuideim a’ mìneachadh carson.
Kantesti AI trend analysis is most informative when tests are taken at comparable points—ideally avoiding strenuous exercise for 48 hours and noting alcohol, illness, and new supplements. The alcohol cessation biomarker timeline describes what may normalise first.
Food and supplement myths that can delay liver care
No juice cleanse, herbal product, or supplement can reliably remove cirrhosis scar tissue. A Mediterranean-style eating pattern, adequate protein, diabetes management, and avoidance of hepatotoxic supplements can support liver health, but they are not substitutes for identifying the cause of fibrosis.
People with cirrhosis are sometimes told to avoid all protein, which can worsen muscle loss and frailty. Unless there is a specific temporary instruction during severe hepatic encephalopathy, many patients need roughly 1.2 to 1.5 g protein per kg body weight daily, divided across meals, under dietetic guidance.
Be wary of products marketed as detoxifiers. Concentrated turmeric, kava, black cohosh, and multi-ingredient bodybuilding or slimming supplements have all been linked to liver injury in case series, and products may not contain what their labels claim. Our evidence-based liver food guide separates supportive dietary habits from marketing claims.
If fluid retention develops, sodium restriction often matters more than fluid restriction. A common target is less than 2 g sodium daily, but diuretics, kidney function, blood pressure, and nutritional adequacy require personalised oversight rather than an internet meal plan.
When cirrhosis symptoms become urgent
Vomiting blood, black tarry stool, confusion, fever with abdominal swelling, severe shortness of breath, or rapidly worsening jaundice are emergency symptoms in someone with known or suspected cirrhosis. These signs can represent variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, kidney injury, or acute-on-chronic liver failure.
New confusion or a reversed sleep-wake cycle is not simply fatigue in cirrhosis. It may indicate hepatic encephalopathy, especially if accompanied by constipation, dehydration, infection, gastrointestinal bleeding, sedative use, or a high ammonia result; ammonia alone, however, does not reliably diagnose or grade encephalopathy.
A distended abdomen can reflect ascites, but it can also arise from obesity, bowel distension, ovarian disease, or heart failure. Fever, tenderness, low blood pressure, or worsening kidney function in a person with ascites should be assessed immediately because infection can be subtle and dangerous.
For non-emergency uncertainty, write down symptoms, medicines, alcohol intake, supplements, and date-stamped weights before calling a clinician. A liosta-gnàthachaidh deuchainn-fala can make that conversation more efficient.
A practical liver appointment checklist that changes decisions
The best liver appointment includes prior laboratory reports, a realistic alcohol and medication history, metabolic history, and any imaging reports. These details let clinicians distinguish a transient enzyme result from a multi-year pattern suggesting fibrosis.
Bring every result you can find, including CBC, liver panel, INR, ferritin, hepatitis tests, ultrasound reports, and elastography values in kPa. A single result can be noisy; three results spanning 18 months can show whether platelets are falling or bilirubin is stable. Our treòir coimeas toradh taobh le taobh explains what changes are usually meaningful.
Ask four direct questions: What is the likely cause? What fibrosis stage is suspected? Do I need elastography or hepatology referral? Which symptoms should send me to urgent care? If cirrhosis is confirmed, ask about six-monthly ultrasound surveillance for liver cancer and whether endoscopy is needed to assess varices.
As of September 4, 2026, our doctors still recommend that AI-generated explanations be treated as preparation, not diagnosis. Kantesti's clinical work is reviewed with oversight from the Bòrd Comhairleachaidh Meidigeach, and the final decision about cirrhosis belongs with the treating clinician who can examine you and order confirmatory testing.
Ceistean Bitheanta
An urrainn dhut cirrhosis a bhith agad le h-enzyman grùthan àbhaisteach?
Tha. Chan eil ALT agus AST àbhaisteach a’ cur às do cirrhosis oir tha na h-enzyman sin a’ nochdadh leòn gnàthach ann an ceallan ae an àite na tha de stuth-dhealbh stèidhichte ann. Faodaidh cirrhosis dìolaidh nochdadh le ALT agus AST taobh a-staigh raon-ama obair-lann, gu sònraichte ann an galair ae metabolach. Faodaidh cunntas truinnsear nas ìsle na 150 × 10⁹/L, FIB-4 de 2.67 no barrachd, elastography neo-àbhaisteach, ìrean albumin ìosal, no INR ag èirigh a bhith a’ toirt seachad comharran nas feumaile na na h-enzyman leis fhèin.
Dèad a’ chiad chomharran rabhaidh aillseachd?
Faodaidh comharran tràth de cirrhosis a bhith a’ toirt a-steach sgìths leantainneach, droch bhiadh, tachas, bruis furasta, lughdachadh fulangas eacarsaich, atharrachaidhean cadail, agus lànachd bhoilg, ach chan eil comharraidhean aig mòran dhaoine. Tha buidheachas, fual dorcha, stòl bàn, sèid nan adhbrann, lionn bhoilg, troimh-chèile, cuir a-mach fuil, agus stòl dubh buailteach a bhith nan soidhnichean nas fhaide air adhart no èiginneach. Chan urrainn do chomharran a-mhàin cirrhosis a dhearbhadh, mar sin mar as trice tha feum air pannal grùthan, CBC le truinnsearan, INR, albsaimin, agus measadh fibrosis.
Dè an àireamh truinnsear a tha a’ nochdadh cirrhosis?
Faodaidh cunntas platelet fo 150 × 10⁹/L amharas a thogail airson sìtheadh grùthan adhartach no bruthadh-fala portal nuair a mhaireas e agus a thìmeas sìos, ach chan eil e a’ dearbhadh cirrhosis. Faodaidh cruinneachadh platelet, tinneasan bhìorasach, thrombocytopenia dìonach, cungaidhean-leigheis, dìth beathachaidh, agus easbaidhean smior cuideachd an cunntas a lughdachadh. Tha tuiteam adhartach, leithid 220 gu 135 × 10⁹/L thairis air dà bhliadhna còmhla ri AST àrdachadh agus FIB-4 àrd, nas fhiosraiche na aon leughadh gu math ìosal.
Dè tha sgòr FIB-4 a' ciallachadh airson cirrhosis?
Chan eil FIB-4 a' dearbhadh cirrhosis, ach tha e a' measadh an cunnart bho fibrosis adhartach bho aois, AST, ALT, agus truinnsearan. Ann an inbhich nas òige na 65, tha sgòr fo 1.3 mar as trice a' comharrachadh cunnart ìosal, feumaidh 1.3 gu 2.66 measadh neo-ionnsaigheach a bharrachd, agus tha 2.67 no nas àirde a' gealltainn measadh speisealta. Ann an inbhich nas sine na 65, thathas a' cleachdadh stairsneach os cionn 2.0 gu cumanta gus ceàrr-dhearbhaidhean co-cheangailte ri aois a lughdachadh.
An urrainn do cirrhosis a bhith a’ dol am feabhas ma thèid a ghlacadh tràth?
Faodaidh fibrosis tràth-ìre leasachadh nuair a thèid an adhbhar bunaiteach a thoirt air falbh no a smachdachadh, a’ gabhail a-steach dìth-alcol leantainneach, làimhseachadh soirbheachail air bhìoras hepatitis, call cuideim ann an galair ae metabolach, no làimhseachadh galar fèin-ana-mearachdach. Is dòcha nach tig cirrhosis stèidhichte air ais gu tur, ach faodar duilgheadasan agus lotan a bharrachd a lughdachadh gu tric le cùram speisealta. Faodaidh call cuideim leantainneach de 7% gu 10% leasachadh steatohepatitis a dhèanamh ann an mòran dhaoine le galair ae metabolach, ged a tha toraidhean eadar-dhealaichte eadar euslaintich.
Cuin a bu chòir dhomh a dhol dhan ospadal airson cirrhosis a dh’fhaodadh a bhith ann?
Faigh cùram èiginn airson cuir a-mach fuil, stòl tarraiceach dubh, troimh-chèile ùr, faochadh, fiabhras le sèid bhoilg, buidheachas dona, no giorrad analach a tha a’ fàs gu luath. Faodaidh na comharraidhean sin a bhith a’ nochdadh fuil bhovareices, galar ann an lionn ascitic, encephalopathy hepatic, no fàilligeadh grùthan mòr agus cha bu chòir dhaibh feitheamh ri deuchainnean fala ath-aithris san ospadal. Ma tha comharraidhean tlàth agad ach gu bheil bilirubin nas àirde na 34 µmol/L, tha INR nas àirde na 1.3 às aonais anticoagulants, no gu bheil truinnsearan a’ tuiteam, cuir fios gu neach-clionaigeach sa bhad airson comhairle.
Faigh Mion-sgrùdadh Deuchainn Fala le Cumhachd AI an-diugh
Thig còmhla ri còrr is 2 mhillean neach air feadh an t-saoghail a tha a’ earbsa Kantesti airson mion-sgrùdadh sa bhad, ceart air deuchainnean obair-lann. Luchdaich suas na toraidhean deuchainn fala agad agus faigh mìneachadh coileanta air biomarcair 15,000+ ann an diogan.
📚 Foillseachaidhean Rannsachaidh le Iomraidhean
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti Research Team. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Zenodo. https://doi.org/10.5281/zenodo.18262555. ResearchGate and Academia.edu availability links are maintained through the publication record.. Rannsachadh Leigheis AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti Research Team. (2026). Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test. Zenodo. https://doi.org/10.5281/zenodo.18316300. ResearchGate and Academia.edu availability links are maintained through the publication record.. Rannsachadh Leigheis AI Kantesti.
📖 Iomraidhean Meidigeach Taobh a-muigh
⚕️ Àicheadh Meidigeach
Tha an artaigil seo dìreach airson adhbharan foghlaim agus chan eil e a’ dèanamh comhairle mheidigeach. Cuir fios an-còmhnaidh gu solaraiche cùram slàinte teisteanasach airson co-dhùnaidhean breithneachaidh is leigheis.
Comharran earbsa E-E-A-T
Eòlas
Lèirmheas clionaigeach air a stiùireadh le lighiche air sruthan-obrach mìneachaidh obair-lann.
Eòlas
Fòcas air leigheas obair-lann air mar a bhios bith-chomharraidhean (biomarkers) a’ giùlan ann an co-theacsa clionaigeach.
Ùghdarrasachd
Air a sgrìobhadh le Dr. Thomas Klein le ath-sgrùdadh le Dr. Sarah Mitchell agus Prof. Dr. Hans Weber.
Earbsachd
Mìneachadh stèidhichte air fianais le slighean leanmhainn soilleir gus dragh a lughdachadh.